The 31 trials had 39,605 patients who were randomised and received at least one dose of study medication (intention-to-treat population).
Outcome measurements included all patients who were randomised and received at least one dose of study medication (intention-to-treat analysis).
Data were analyzed on the basis of randomly assigned groups, regardless of participants' subsequent medication (intention-to-treat analysis), and expressed as the mean ± SEM.
The population of this retrospective analysis consisted of all normally menstruating women randomized to any of the two treatment sequences, enrolled to receive either of the study treatments and having treated at least one episode of menstrual migraine with both medications (intention-to-treat population).
This analysis was carried out in all normally menstruating women randomized to any of the two treatment sequences, having not positively refused to receive either study treatment and having treated at least one episode of menstrual migraine with both medications (intention-to-treat population).
The results are presented on the basis of patients who received at least one dosis of study medication, the intention to treat population.
Sewitch et al [ 7] suggest that health beliefs play a stronger role than quality of life or patient/physician relationship in the variance in medication taking intention, but that those with more severe disease were more likely to consider the costs and the benefits rather than just the costs as is the case with those with less severe disease.
Intention-to-treat analysis included all randomised patients who received at least one dose of study medication (modified intention-to-treat analysis).
All efficacy evaluations were performed on the population of randomized patients who received at least one dose of study medication, the intention-to-treat (ITT) population.
As noted above regarding cautions in generalisability, further research is warranted to explore medication-taking intentions and associated patient characteristics in real life, with real patients confronted with actual risk and effectiveness information and having to make shared decisions with their doctors or nurses.
Other 0 0 0 – Question 2. Medication of second intention 1.
